Grail, INC 10-Q quarterly reports

GRAIL Inc. reported a 37% increase in screening revenue for Q1 2026, driven by higher Galleri test volumes, while net loss narrowed compared to the prior year.

GRAIL, Inc. reported reduced net losses in Q3 2025, driven by increased Galleri sales and cost optimization, while securing $435 million in new financing and presenting strong clinical trial data.

GRAIL, Inc. reports an 11% increase in total revenue for Q2 2025, driven by Galleri sales volume, while significantly narrowing net losses and continuing strategic restructuring efforts.

GRAIL Inc. reports a 24% increase in screening revenue for the first quarter of 2025, driven by higher Galleri test sales volume, while continuing to manage costs and pursue regulatory approval.

GRAIL, Inc. reports a net loss of $125.7 million for the third quarter of 2024, following its spin-off from Illumina and a restructuring plan.

GRAIL Inc. reported a significant net loss for the second quarter of 2024, driven by goodwill and intangible asset impairments, and announced a restructuring plan to focus on its core multi-cancer early detection business.